CN106714831A - 新的抗‑rnf43抗体和使用方法 - Google Patents

新的抗‑rnf43抗体和使用方法 Download PDF

Info

Publication number
CN106714831A
CN106714831A CN201580033599.1A CN201580033599A CN106714831A CN 106714831 A CN106714831 A CN 106714831A CN 201580033599 A CN201580033599 A CN 201580033599A CN 106714831 A CN106714831 A CN 106714831A
Authority
CN
China
Prior art keywords
antibody
rnf43
seq
cell
people
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580033599.1A
Other languages
English (en)
Chinese (zh)
Inventor
M.布恩坦拉特
D.罗坎
D.刘
S.J.戴拉
M.奥加伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbo Wisch Te Musen Tex LLC
AbbVie Stemcentrx LLC
Original Assignee
Abbo Wisch Te Musen Tex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbo Wisch Te Musen Tex LLC filed Critical Abbo Wisch Te Musen Tex LLC
Publication of CN106714831A publication Critical patent/CN106714831A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201580033599.1A 2014-04-21 2015-04-21 新的抗‑rnf43抗体和使用方法 Pending CN106714831A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461982294P 2014-04-21 2014-04-21
US61/982294 2014-04-21
PCT/US2015/026904 WO2015164392A2 (en) 2014-04-21 2015-04-21 Novel antii-rnf43 antibodies and methods of use

Publications (1)

Publication Number Publication Date
CN106714831A true CN106714831A (zh) 2017-05-24

Family

ID=54333409

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580033599.1A Pending CN106714831A (zh) 2014-04-21 2015-04-21 新的抗‑rnf43抗体和使用方法

Country Status (18)

Country Link
US (1) US20170073430A1 (2)
EP (1) EP3134121A4 (2)
JP (1) JP2017518040A (2)
KR (1) KR20170010764A (2)
CN (1) CN106714831A (2)
AU (1) AU2015249887A1 (2)
BR (1) BR112016024525A2 (2)
CA (1) CA2946308A1 (2)
CL (2) CL2016002667A1 (2)
CR (1) CR20160486A (2)
DO (1) DOP2016000283A (2)
EA (1) EA201692100A8 (2)
IL (1) IL248399A0 (2)
MA (1) MA39896A (2)
MX (1) MX2016013857A (2)
PH (1) PH12016502061A1 (2)
SG (1) SG11201608715WA (2)
WO (1) WO2015164392A2 (2)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112480250A (zh) * 2020-12-23 2021-03-12 上海交通大学 一种抗人骨桥蛋白的抗体及其应用
CN112654363A (zh) * 2018-07-09 2021-04-13 瑟罗泽恩公司 组织特异性wnt信号增强分子和其用途
CN114634576A (zh) * 2021-05-26 2022-06-17 中元汇吉生物技术股份有限公司 抗pivka-ii单克隆抗体及其应用
CN116120444A (zh) * 2023-02-28 2023-05-16 中国人民解放军军事科学院防化研究院 一种用于检测SARS-CoV-2病毒N蛋白的纳米抗体及检测卡制备
CN117801108A (zh) * 2023-12-06 2024-04-02 无锡傲锐东源生物科技有限公司 抗人mdm2蛋白单克隆抗体及其杂交瘤细胞株和应用
CN118652345A (zh) * 2024-06-28 2024-09-17 杭州华葵金配生物科技有限公司 幽门螺旋杆菌b型尿素酶抗体及其应用
CN119462949A (zh) * 2025-01-09 2025-02-18 中国农业科学院农业质量标准与检测技术研究所 一种抗β-内酰胺酶的抗体或其抗原结合片段、生物产品及其应用
US12240876B2 (en) 2020-11-16 2025-03-04 Surrozen Operating, Inc. Liver-specific Wnt signal enhancing molecules and uses thereof

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI638833B (zh) 2010-11-30 2018-10-21 中外製藥股份有限公司 細胞傷害誘導治療劑
US20190194319A1 (en) * 2016-05-20 2019-06-27 Abbvie Stemcentrx Llc Anti-ascl1 antibodies and methods of use
EP3568158A4 (en) * 2017-01-11 2020-11-18 The Board of Trustees of the Leland Stanford Junior University R-SPONDIN SUBSTITUTION MOLECULES (RSPO)
WO2018140821A1 (en) * 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
JP2020518584A (ja) * 2017-05-02 2020-06-25 中外製薬株式会社 細胞傷害誘導治療剤
EP3765054A4 (en) * 2018-01-19 2022-01-12 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR TARGETING GAMMA DELTA T LYMPHOCYTES USING CHIMERIC ANTIGEN RECEPTORS
US12016885B2 (en) * 2018-11-06 2024-06-25 Alsatech, Inc. Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab
CA3141632A1 (en) 2019-06-21 2020-12-24 Regeneron Pharmaceuticals, Inc. Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors
US20240002479A1 (en) * 2020-11-23 2024-01-04 The Regents Of The University Of Michigan Single-chain antibody against flavivirus ns1 protein
WO2022169872A1 (en) * 2021-02-03 2022-08-11 Genentech, Inc. Multispecific binding protein degrader platform and methods of use
CA3211478A1 (en) * 2021-03-16 2022-09-22 Naoya Tsurushita Bifunctional molecules for treatment of immune disorders
US20240401145A1 (en) * 2021-09-28 2024-12-05 Paul Scherrer Institut Method for predicting the response of a patient diagnosed with cancer to treatment and/or imaging with a compound targeting cck2-r, and compound for use in methods of selectively treating and/or imaging cancer
EP4562131A2 (en) * 2022-07-25 2025-06-04 Memorial Sloan Kettering Cancer Center Manufacturing processes for adoptive cell therapies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101613405A (zh) * 2002-06-06 2009-12-30 肿瘤疗法科学股份有限公司 与人结肠癌相关的基因和多肽
WO2013054307A2 (en) * 2011-10-14 2013-04-18 Novartis Ag Antibodies and methods for wnt pathway-related diseases
WO2013130364A1 (en) * 2012-02-28 2013-09-06 Novartis Ag Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140371A2 (en) * 2006-05-30 2007-12-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101613405A (zh) * 2002-06-06 2009-12-30 肿瘤疗法科学股份有限公司 与人结肠癌相关的基因和多肽
WO2013054307A2 (en) * 2011-10-14 2013-04-18 Novartis Ag Antibodies and methods for wnt pathway-related diseases
WO2013130364A1 (en) * 2012-02-28 2013-09-06 Novartis Ag Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAOTAKA UCHIDA等: "Ring Finger Protein 43 as a New Target for Cancer Immunotherapy", 《CLINICAL CANCER RESEARCH》 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112654363A (zh) * 2018-07-09 2021-04-13 瑟罗泽恩公司 组织特异性wnt信号增强分子和其用途
US12466884B2 (en) 2018-07-09 2025-11-11 Surrozen Operating, Inc. Tissue-specific WNT signal enhancing molecules and uses
US12240876B2 (en) 2020-11-16 2025-03-04 Surrozen Operating, Inc. Liver-specific Wnt signal enhancing molecules and uses thereof
CN112480250B (zh) * 2020-12-23 2022-03-15 上海交通大学 一种抗人骨桥蛋白的抗体及其应用
CN112480250A (zh) * 2020-12-23 2021-03-12 上海交通大学 一种抗人骨桥蛋白的抗体及其应用
CN114634576A (zh) * 2021-05-26 2022-06-17 中元汇吉生物技术股份有限公司 抗pivka-ii单克隆抗体及其应用
CN114634576B (zh) * 2021-05-26 2023-07-25 中元汇吉生物技术股份有限公司 抗pivka-ii单克隆抗体及其应用
CN116120444A (zh) * 2023-02-28 2023-05-16 中国人民解放军军事科学院防化研究院 一种用于检测SARS-CoV-2病毒N蛋白的纳米抗体及检测卡制备
CN117801108A (zh) * 2023-12-06 2024-04-02 无锡傲锐东源生物科技有限公司 抗人mdm2蛋白单克隆抗体及其杂交瘤细胞株和应用
CN117801108B (zh) * 2023-12-06 2024-06-07 无锡傲锐东源生物科技有限公司 抗人mdm2蛋白单克隆抗体及其杂交瘤细胞株和应用
CN118652345A (zh) * 2024-06-28 2024-09-17 杭州华葵金配生物科技有限公司 幽门螺旋杆菌b型尿素酶抗体及其应用
CN118652345B (zh) * 2024-06-28 2025-04-15 杭州华葵金配生物科技有限公司 幽门螺旋杆菌b型尿素酶抗体及其应用
CN119462949A (zh) * 2025-01-09 2025-02-18 中国农业科学院农业质量标准与检测技术研究所 一种抗β-内酰胺酶的抗体或其抗原结合片段、生物产品及其应用
CN119462949B (zh) * 2025-01-09 2025-04-01 中国农业科学院农业质量标准与检测技术研究所 一种抗β-内酰胺酶的抗体或其抗原结合片段、生物产品及其应用

Also Published As

Publication number Publication date
JP2017518040A (ja) 2017-07-06
WO2015164392A8 (en) 2016-12-29
WO2015164392A3 (en) 2015-12-23
MA39896A (fr) 2017-03-01
CA2946308A1 (en) 2015-10-29
EP3134121A4 (en) 2017-11-08
SG11201608715WA (en) 2016-11-29
DOP2016000283A (es) 2016-11-30
EA201692100A8 (ru) 2018-11-30
PH12016502061A1 (en) 2016-12-19
KR20170010764A (ko) 2017-02-01
BR112016024525A2 (pt) 2017-10-10
CL2016002667A1 (es) 2017-07-07
MX2016013857A (es) 2017-07-14
AU2015249887A1 (en) 2016-11-03
CL2017003240A1 (es) 2018-06-01
US20170073430A1 (en) 2017-03-16
WO2015164392A2 (en) 2015-10-29
CR20160486A (es) 2017-02-20
EA201692100A1 (ru) 2017-02-28
IL248399A0 (en) 2016-11-30
EP3134121A2 (en) 2017-03-01

Similar Documents

Publication Publication Date Title
US9777071B2 (en) Anti-DPEP3 antibodies and methods of use
US10308721B2 (en) Anti-DLL3 antibodies and drug conjugates for use in melanoma
JP6515111B2 (ja) 新規の抗クローディン抗体および使用方法
US10428156B2 (en) Anti-MFI2 antibodies and methods of use
US20170073430A1 (en) Novel anti-rnf43 antibodies and methods of use
JP2019500335A (ja) 新規の抗クローディン抗体及び使用方法
CN107530443A (zh) 工程化的位点特异性抗体和使用方法
US20190000969A1 (en) Novel anti-upk1b antibodies and methods of use
TW201726748A (zh) 新穎抗－ｍｍｐ１６抗體及使用方法
US20190127476A1 (en) Novel anti-tnfrsf21 antibodies and methods of use
TW201725217A (zh) 新穎抗－ｔｎｆｓｆ９抗體及使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: M. Boone Tanlate

Inventor after: D. Rokkan

Inventor after: D.Liu

Inventor after: Dylla Scott J

Inventor after: M. Aojiayi

Inventor after: S.A. Williams

Inventor before: M. Boone Tanlate

Inventor before: D. Rokkan

Inventor before: D.Liu

Inventor before: Dylla Scott J

Inventor before: M. Aojiayi

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170524